Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 in Alzheimer's Disease (MCI or Mild Dementia)
NCT05619692Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of dalzanemdor in Alzheimer's disease (AD), sponsored by Supernus Pharmaceuticals, Inc.. Started Nov 2022; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05619692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619692.